Literature DB >> 3839805

Radiotherapy of severe ophthalmic Graves' disease.

B M van Ouwerkerk, R Wijngaarde, G Hennemann, J G van Andel, E P Krenning.   

Abstract

The effects of orbital irradiation on Ophthalmic Graves' Disease (OGD) were evaluated in 24 patients. All patients were irradiated after a median duration of eye symptoms of 12 months (range 3-36 months). Irradiation therapy was performed for loss of visual acuity, progressive diplopia and/or keratitis due to recent progression of eye symptoms. During a follow up period of 2-4.5 years, in 11 patients after irradiation, a mean decrease in proptosis oculi of 5.1 mm was found while 8 of these patients showed a mean increase in visual acuity of 0.26. Apparently, a decrease of activity of the inflammatory process in retrobulbar tissues can be achieved after irradiation, over a longer period of time in many patients. Furthermore concomitantly administered corticosteroids could be tapered off completely in all patients. Treatment of severe OGD of recent onset with irradiation, in combination with a short course of prednisone is very effective. This study also shows that prednisone treatment alone is not very successful because of the high recurrence rate of eye sings after decrease of the dose and the many side effects of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839805     DOI: 10.1007/BF03348485

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

1.  Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves' disease.

Authors:  J BROWN; J W COBURN; R A WIGOD; J M HISS; J T DOWLING
Journal:  Am J Med       Date:  1963-06       Impact factor: 4.965

2.  Computed tomography in Graves' ophthalmopathy.

Authors:  D Enzmann; W H Marshal; A R Rosenthal; J P Kriss
Journal:  Radiology       Date:  1976-03       Impact factor: 11.105

3.  Prednisone in emergency treatment of malignant exophthalmos.

Authors:  S C Werner
Journal:  Lancet       Date:  1966-05-07       Impact factor: 79.321

4.  Supervoltage orbital radiotherapy for Graves' ophthalmopathy.

Authors:  S S Donaldson; M A Bagshaw; J P Kriss
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

5.  Pattern EPS in endocrine orbitopathy.

Authors:  R Wijngaarde; G H van Lith
Journal:  Doc Ophthalmol       Date:  1980-04-15       Impact factor: 2.379

6.  Prevalence of increased intraocular pressure in Graves' disease--evidence of frequent subclinical ophthalmopathy.

Authors:  G T Gamblin; D G Harper; P Galentine; D R Buck; B Chernow; C Eil
Journal:  N Engl J Med       Date:  1983-02-24       Impact factor: 91.245

7.  Severe ophthalmic Graves' disease and autoimmune thyroid disorders with different clinical expression.

Authors:  M Van Ouwerkerk; E N Janssens; R Wijngaarde; E P Krenning
Journal:  Neth J Med       Date:  1983       Impact factor: 1.422

8.  Demonstration of a circulating autoantibody against a soluble eye-muscle antigen in Graves' ophthalmopathy.

Authors:  K Kodama; H Sikorska; P Bandy-Dafoe; R Bayly; J R Wall
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

9.  Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.

Authors:  L Bartalena; C Marcocci; L Chiovato; M Laddaga; G Lepri; D Andreani; G Cavallacci; L Baschieri; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement.

Authors:  K Yamamoto; K Saito; T Takai; S Yoshida
Journal:  Endocrinol Jpn       Date:  1982-08
View more
  4 in total

1.  DEGRO practical guidelines for the radiotherapy of non-malignant disorders - Part IV: Symptomatic functional disorders.

Authors:  Gabriele Reinartz; Hans Theodor Eich; Fabian Pohl
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

2.  Early detection of P-VEP and PERG changes in ophthalmic Graves' disease.

Authors:  L Spadea; G Bianco; T Dragani; E Balestrazzi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

3.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

4.  [Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; G Gusek-Schneider; S Barth; J Hensen; F Wolf; G O Naumann; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-09       Impact factor: 4.033

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.